A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Cardiovascular Disease Management

The sponsor maintains a focused research portfolio in cardiovascular therapeutics, with particular emphasis on conditions affecting cardiac function and vascular health. Their clinical investigations target patients experiencing acute coronary syndromes and related cardiovascular events requiring specialized medical intervention.

  • Acute Myocardial Infarction Treatment
  • Coronary Artery Disease Interventions
  • Cardiac Event Prevention Strategies

Research activities concentrate on developing therapeutic approaches for patients undergoing percutaneous coronary intervention and those at risk of major adverse cardiovascular events, addressing critical needs in emergency cardiac care and secondary prevention.

Antiplatelet and Antithrombotic Therapy

A significant area of therapeutic interest involves the investigation of antiplatelet agents and their role in preventing thrombotic complications. The research encompasses novel approaches to managing platelet aggregation in high-risk cardiovascular populations.

  • Dual Antiplatelet Therapy Optimization
  • Thrombosis Prevention in Acute Coronary Settings
  • Platelet Function Modulation

Clinical programmes explore the balance between preventing ischemic events and managing bleeding risk in patients with acute coronary syndrome, particularly those requiring interventional procedures.

Interventional Cardiology Support

The sponsor demonstrates commitment to advancing care in interventional cardiology, supporting research that enhances outcomes for patients undergoing invasive cardiac procedures. Their studies focus on pharmacological support during and after coronary stenting and other revascularization techniques.

  • Post-Procedural Complication Prevention
  • Stent Thrombosis Risk Reduction
  • Periprocedural Medication Strategies

Research initiatives address the specific needs of patients with ST-elevation myocardial infarction and non-ST-elevation acute coronary syndrome, aiming to improve both immediate procedural success and long-term cardiovascular outcomes.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of bilastine for effectiveness, safety and quality of life in children aged 6 to 12 years with allergic rhinoconjunctivitis

    Recruiting

    3 1 1 1
    Investigated drugs:
    Italy Poland Spain
  • Study comparing bilastine, ebastine, and desloratadine in preventing histamine-induced skin reactions in healthy volunteers

    Not recruiting

    3 1 1
    Spain